Helping Experts Accelerate Rare Treatments Act of 2020
This bill addresses rare diseases, including by requiring the Food and Drug Administration to ensure the inclusion of rare disease experts and staff members in various parts of the drug review process.
The bill also requires certain reports to address issues related to rare diseases and drugs for treating such diseases (sometimes referred to as orphan drugs if the rarity of the disease makes it difficult for the drug to be profitable).
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line